The authors reviewed here CDI prophylactic treatment strategies and their implementation in clinical practice. Based on the results retrieved, there are no proven effective, evidenced-based prophylaxis options for primary CDI. As for secondary prevention, FMT is considered the option of choice in patients with multiple recurrences.
Bezlotoxumab can be added to standard treatment for patients at high risk for R-CDI. The most promising strategies are those aimed at reducing changes in intestinal microbiota and development of a new effective non–toxin-based vaccine.